Pre-Conference Workshop Day

Workshop A - Tuesday July 11 2023

Exploring Strategies to Reduce Vector Dosage & Minimize AAV Safety Concerns

9:30AM - 12:30PM

 

Effectively reducing the doses of AAV vectors required to successfully treat patients could be the key to improving the overall safety of AAV gene therapies. However, this is easier said than done and there are several obstacles to overcome for this to become a reality for gene therapies. Join this deep dive session to learn about the latest advancements reducing AAV vector dosage

 

Attend this workshop to:

  • Understand the safety issues with high vector doses
  • Explore the advancements made towards re-dosing to minimize high vector dose
    requirements
  • Clarify the vector genomes are accurate to ensure a functional product is produced
    and use the minimal vector dose required
Speaker Resizing

Abraham Scaria
Chief Scientific Officer
AGTC

Workshop B - Tuesday July 11 2023

Assessing the Negative AAV Safety Events & the Impact on Preclinical Testing

1:30PM – 4:30PM

 

Participate in this collaborative session to understand the complex landscape of identifying adverse safety events in preclinical trials and discuss the latest advancements to improve the prediction and monitoring of preclinical safety events to minimize preclinical delays and improve translational success of AAV gene therapies.

 

Join this workshop to:

  • Highlight important safety events and trying to identify the root cause
  • Review preclinical data to better anticipate AAV safety events
  • Explore strategies to mitigate these negative safety events in future preclinical
    programs
MansuoShannonjpeg

Mansuo Shannon
Chief Scientific Officer
Prevail Therapeutics